共 69 条
[1]
Lipton RB(2007)Migraine prevalence, disease burden, and the need for preventive therapy Neurology 68 343-349
[2]
Bigal ME(2017)Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet 390 1211-1259
[3]
Diamond M(2008)Direct cost burden among insured US employees with migraine Headache 48 553-563
[4]
Hawkins K(2007)Indirect cost burden of migraine in the United States J Occup Environ Med 49 368-374
[5]
Wang S(2009)The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis Value Health 12 55-64
[6]
Rupnow M(1999)Burden of migraine in the United States: disability and economic costs Arch Intern Med 159 813-818
[7]
Hawkins K(2018)The American Headache Society position statement on integrating new migraine treatments into clinical practice Headache 59 1-18
[8]
Wang S(2018)ARISE: a phase 3 randomized trial of erenumab for episodic migraine Cephalalgia 38 1026-1037
[9]
Rupnow MF(2018)Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study Lancet 392 2280-2287
[10]
Hazard E(2017)Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial Lancet Neurol 16 425-434